Virtual Diabetes Group Visits Across Health Systems
The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).
Conditions:
🦠 T2DM (Type 2 Diabetes Mellitus) 🦠 Hypertension 🦠 Heart Disease Chronic 🦠 Stroke 🦠 Hyperlipidemias 🦠 Peripheral Vascular Diseases 🦠 Obesity
🗓️ Study Start (Actual) 3 May 2024
🗓️ Primary Completion (Estimated) 30 April 2025
✅ Study Completion (Estimated) 31 May 2026
👥 Enrollment (Estimated) 720
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE2
Locations:
📍 Chicago, Illinois, United States
📍 Orland Park, Illinois, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Patient at a participating clinic (at least one visit in year prior to first GV)
    • * Type 2 diabetes
    • * ≥ 18 years old
    • * A1C\>8% within 6 months prior to first GV (we will first recruit patients with A1C\>9%, then if spaces still available A1C\>8.5%, then if spaces still available A1C\>8%)
    • * At least one additional cardiovascular condition (hypertension, heart disease, stroke, hyperlipidemia, peripheral vascular disease, or BMI ≥ 30)
    • * English or Spanish speaking
    • * PCP assented to recruiting patient
    • * Patient provides written consent
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 17 October 2023
  • First Submitted that Met QC Criteria 17 October 2023
  • First Posted 23 October 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 18 July 2024
  • Last Update Posted 22 July 2024
  • Last Verified July 2024